Structure-Based Drug Design Summit Returns This June

With tightening budgets and increasing pressure to de-risk R&D, pharma and biotech are shifting their focus toward smarter, more efficient drug design. Companies are investing more in enabling technologies—from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM, NMR, and X-ray crystallography—to improve rational drug design and enhance decision-making early in discovery.

The 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies, you’ll gain insights into how leading scientists are leveraging Cryo-EM, NMR, X-ray crystallography, and AI to solve high-value targets and drive rational drug design across small molecules, peptides, biologics, and vaccines.

With coverage of design of TPDs, molecular glues, vaccines, antibodies, and mRNA, GPCRs and membrane protein targeting therapeutics plus much more!

The field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists, medicinal chemists, protein engineers, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.

Companies attending include:

Sanofi, Takeda, Remix Therapeutics, Eli Lilly & Co, Vertex Pharmaceuticals, Tango Therapeutics, Flare Therapeutics, AstraZeneca, Biogen

+ many more

Find out more about our expert speakers and their sessions by downloading our full event guide here https://ter.li/4fgvwa

Secure your spot and register today https://ter.li/zwhs8q